Drug intelligence / Profile preview

ixekizumab + Jueyin Granules

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral, Subcutaneous

Overview

Ixekizumab + Jueyin Granules is a combination therapy that pairs a biologic medication (ixekizumab) with Chinese herbal medicine (Jueyin Granules). Ixekizumab is a humanized monoclonal antibody that selectively binds to interleukin-17A (IL-17A) and prevents its interaction with the IL-17 receptor, thereby reducing inflammation in psoriasis. Jueyin Granules is a Chinese herbal medicine formulation that may help reduce psoriasis relapse rates. This combination approach aims to leverage the rapid symptomatic relief provided by ixekizumab with the potential relapse-reducing properties of Chinese herbal medicine.

Brand names: Taltz + Jueyin Granules

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on ixekizumab + Jueyin Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ixekizumab + Jueyin Granules.

Explore the full profile